findmyKOL

Harold Moses, MD

Basic profile

Vanderbilt University Medical Center

ORCIDNone on fileNPI
RegionNashville, TN · SoutheastSpecialtyNeurologyFocusNeurology
Last active 2020findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding1985–2020Why? →

Harold Moses is a Neurology physician affiliated with Vanderbilt University Medical Center. OpenAlex indexes 28 publications with 1,302 citations (h-index 15).

Overview

Scholarship

indexed output and impact (OpenAlex)
28publications

Distinct works indexed by OpenAlex.

1,302citations

Total citations across indexed works.

15h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
20companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
15NIH grants · 1985–2020

Federally funded research awards.

View funding

Industry payments

20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

20 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    49%
    Gabapentinoids15.4%
    Gabapentin96%Pregabalin4%
    Part D<11 patients
    Potassium Channel Blocker5.2%
    Dalfampridine Er89%Ampyra11%
    Part D<11 patients

    + 14 more classes in this area

  • Cancer & immunology

    26.8%
    Other immunosuppressants6.9%
    Tecfidera45%Dimethyl Fumarate45%Vumerity9%
    Part D<11 patients
    Other immunostimulants4.6%
    Copaxone74%Glatiramer Acetate26%
    Part D<11 patients

    + 6 more classes in this area

  • Musculoskeletal

    20.7%
    gamma-Aminobutyric Acid-ergic Agonist14%
    Baclofen100%
    Part D98 patients
    Central alpha-2 Adrenergic Agonist4.2%
    Tizanidine Hcl100%
    Part D38 patients

    + 2 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

15 NIH research awards on record, funded 19852020 per NIH RePORTER. The latest:

190 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”